DGX on XNYS, Health Care, Quest Diagnostics Inc., job postings
Measures activity, not value. Not investment advice.
Net income rose 17% to $1.1B over 12 months as latest quarter revenue grew 10%.
GoodInstitutional holders up 4.1% to 1,126 filers in the latest quarter
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.1B, net income $312.0M.
31 Dec 2021RevenueNet incometallest bar $3.1B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$3.1B
$312.0M
30 Jun 2026
$3.0B
$320.0M
31 Mar 2026
$2.9B
$252.0M
31 Dec 2025
$2.8B
$245.0M
30 Sep 2025
$2.8B
$245.0M
30 Jun 2025
$2.8B
$282.0M
31 Mar 2025
$2.7B
$220.0M
31 Dec 2024
$2.6B
$222.0M
30 Sep 2024
$2.5B
$226.0M
30 Jun 2024
$2.4B
$229.0M
31 Mar 2024
$2.4B
$194.0M
31 Dec 2023
$2.3B
$192.0M
30 Sep 2023
$2.3B
$225.0M
30 Jun 2023
$2.3B
$235.0M
31 Mar 2023
$2.3B
$202.0M
31 Dec 2022
$2.3B
$101.0M
30 Sep 2022
$2.5B
$256.0M
30 Jun 2022
$2.5B
$234.0M
31 Mar 2022
$2.6B
$355.0M
31 Dec 2021
$2.7B
$390.0M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$11.8B
$10.8B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+9.1%
+17%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$1.1B
$969.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$10.04
$8.52
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
33.1%
33.3%
33.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
14.6%
14.1%
-8.2%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
9.5%
8.9%
-5.9%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
15.2%
-10.1%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$1.4B
$1.4B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$797.0M
$432.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$5.5B
$5.7B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$4.8B
$5.2B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.73
0.16
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$69.37
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
25.2
29.1
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.4
3.6
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
2.8
2.6
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
3.7
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+10%
$3.1B vs $2.8B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+15%
$166.0M vs $144.0M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$19.8M
bought $0, sold $19.8M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+4.1%
1,126 13F filers vs 1,082
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
93%
102.6M shares held by 13F filers (30 Sep 2026) of 110.0M outstanding (15 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
3.4%
3.7M shares sold short (30 Oct 2026) of 110.0M outstanding (15 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.6
3.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+4.5%
3.6M shares sold short in the report before, 3.7M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
59%
59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
+6.5%
49 vs 46 applications
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$67.0M
the 12 months before: $63.3M
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$300K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
52
52 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
8.7×
52 articles in the last 7 days; its usual week has 6.
Unusual now sharp changes in the last 90 days, compared with its own past
Federal obligations $57.0M, 1.3× a year earlier
Price $258.28 on 20 Nov 2026, +38% over 12 months (12-month range $173.49 to $262.21)
Sharp change
8-K and other filings
WARN layoff notice
Lobbying filing
Insider net buying (open market). Insiders sold a net $36.5M in the last 12 months (the 12 months before: -$43.6M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 49 published in the last 12 months, +6.5% on the 12 months before.Revenue per quarter. Revenue $3.1B in the latest quarter, +10% on a year earlier.Capital spending per quarter. Capital spending $166.0M in the latest quarter, +15% on a year earlier.Institutional holders (13F filers). 1,126 13F filers reported holding it in the latest 13F quarter, +18% on a year earlier.Federal obligations. Federal obligations: $77.9M published in the last 12 months, +30% on the 12 months before.Lobbying spend. Lobbying spend: $300K published in the last 12 months (none in the 12 months before).Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months, -100% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.
Reported lobbying spend: $300K in Q3 2026, $520K in Q1 2023. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
8 Feb 2023
New
Tarplin, Downs & Young, LLCfor Quest Diagnostics
Medicare reimbursementBudget, Health issues, Medicare/Medicaid, Pharmacy
Issues related to innovation, access and affordability of laboratory-based health care modalities in the United States.Health issues, Medicare/Medicaid
Two or more unrelated kinds of records unusual within 30 days
15 May 2025confirmed
Confirmed across sources Institutional holdings and Layoff notices and Short interest and volume
Quest Diagnostics(DGX): had 4.0M shares sold short in the 30 Apr 2025 report, 1.4× the same report last year; it also saw 118 13F filers open a new position in the quarter ended 31 Mar 2025, 1.8× the same quarter last year; and it filed a WARN layoff notice covering 121 workers within 30 days. Three unrelated kinds of activity within 35 days.
Short interest and volume: Short interest spike, became public on 10 May 2025
Institutional holdings: Many funds opening a new position, became public on 15 May 2025
Layoff notices: WARN layoff notice, became public on 1 Jun 2025
Short interest and volume: Short interest spike, became public on 28 May 2025
Short interest and volume: Short interest spike, became public on 11 Jun 2025
The 30 Apr 2025 report against the 24 reports before it.
this reportearliernormal: 2.5MSee the evidence (5 changes)
Short interest and volume: Short interest spike became public on 10 May 2025
Quest Diagnostics had 4.0M shares sold short in the 30 Apr 2025 report, 1.4× the same report last year.
This period
4.0M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
214K
How far from its usual level
+4.8
Same report last year
2.8M
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2025
Quest Diagnostics saw 118 13F filers open a new position in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.
This period
118 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
58.5
Typical spread (median absolute deviation)
7
How far from its usual level
+5.7
Same quarter last year
66
History used
4,200 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 58.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Fires on a WARN notice after 30 days without one; notices within 30 days are summed.
Short interest and volume: Short interest spike became public on 28 May 2025
Quest Diagnostics had 3.9M shares sold short in the 15 May 2025 report, 1.4× the same report last year.
This period
3.9M (the 15 May 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
214K
How far from its usual level
+4.4
Same report last year
2.7M
History used
2,694 days
the 15 May 2025 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jun 2025
Quest Diagnostics had 3.8M shares sold short in the 30 May 2025 report, 1.4× the same report last year.
This period
3.8M (the 30 May 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+4.2
Same report last year
2.7M
History used
2,709 days
the 30 May 2025 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
21 Apr 2022confirmed
Confirmed across sources Government contracts and Lobbying
Quest Diagnostics(DGX): booked $21.9M in federal contract and grant obligations in March 2022, 7.5× the same month last year, while it lobbying on a new issue. Two unrelated kinds of activity within 8 days.
Government contracts: Federal obligations jump, became public on 6 Apr 2022
Lobbying: Lobbying on a new issue, became public on 21 Apr 2022
March 2022 against the 5 months before it.
this monthearliernormal: $2.9MSee the evidence (2 changes)
Government contracts: Federal obligations jump became public on 6 Apr 2022
Quest Diagnostics booked $21.9M in federal contract and grant obligations in March 2022, 7.5× the same month last year.
This period
$21.9M (March 2022)
Normal month (median of 5 earlier)
$2.9M
Typical spread (median absolute deviation)
$973K
How far from its usual level
+13.1
Same month last year
$2.9M
History used
5,295 days
March 20225 earlier monthsnormal: $2.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Lobbying: Lobbying on a new issue became public on 21 Apr 2022
Quest Diagnostics lobbying on a new issue.
New
['BUD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12725905
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
18 May 2021confirmed
Confirmed across sources Government contracts and Filings + Financials and Lobbying and Short interest and volume
Quest Diagnostics(DGX): reported revenue of $2.7B for the quarter ended 31 Mar 2021, 1.5× the same quarter last year; it also booked $12.4M in federal contract and grant obligations in May 2021, 1.7× the same month last year; it also had 9.3M shares sold short in the 15 Jun 2021 report, 2.8× the same report last year; and it reported $340K of lobbying spend for the quarter ended 30 Jun 2021, 1.5× the same quarter last year. Four unrelated kinds of activity within 112 days.
Financials: Quarterly revenue change, became public on 27 Apr 2021
Short interest and volume: Short interest spike, became public on 12 May 2021
Short interest and volume: Short interest spike, became public on 26 May 2021
Government contracts: Federal obligations jump, became public on 4 Jun 2021
Short interest and volume: Short interest spike, became public on 10 Jun 2021
Short interest and volume: Short interest spike, became public on 26 Jun 2021
Government contracts: Federal obligations jump, became public on 6 Jul 2021
Short interest and volume: Short interest spike, became public on 13 Jul 2021
Financials: Quarterly revenue change, became public on 27 Jul 2021
Lobbying: Lobbying spend jump, became public on 22 Jul 2021
Short interest and volume: Short interest spike, became public on 27 Jul 2021
Short interest and volume: Short interest spike, became public on 11 Aug 2021
The quarter ended 31 Mar 2021 against the 8 quarters before it.
this quarterearliernormal: $1.9BSee the evidence (12 changes)
Financials: Quarterly revenue change became public on 27 Apr 2021
Quest Diagnostics reported revenue of $2.7B for the quarter ended 31 Mar 2021, 1.5× the same quarter last year.
This period
$2.7B (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$1.9B
Typical spread (median absolute deviation)
$80.5M
How far from its usual level
+4.0
Same quarter last year
$1.8B
History used
4,657 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $1.9B
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 12 May 2021
Quest Diagnostics had 10.7M shares sold short in the 30 Apr 2021 report, 1.9× the same report last year.
This period
10.7M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+11.5
Same report last year
5.6M
History used
1,218 days
the 30 Apr 2021 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 May 2021
Quest Diagnostics had 10.4M shares sold short in the 14 May 2021 report, 2.2× the same report last year.
This period
10.4M (the 14 May 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+10.9
Same report last year
4.7M
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Government contracts: Federal obligations jump became public on 4 Jun 2021
Quest Diagnostics booked $12.4M in federal contract and grant obligations in May 2021, 1.7× the same month last year.
This period
$12.4M (May 2021)
Normal month (median of 5 earlier)
$1.4M
Typical spread (median absolute deviation)
$872K
How far from its usual level
+8.5
Same month last year
$7.1M
History used
4,991 days
May 20215 earlier monthsnormal: $1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 Jun 2021
Quest Diagnostics had 9.8M shares sold short in the 28 May 2021 report, 2.5× the same report last year.
This period
9.8M (the 28 May 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+10.1
Same report last year
3.9M
History used
1,246 days
the 28 May 2021 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2021
Quest Diagnostics had 9.3M shares sold short in the 15 Jun 2021 report, 2.8× the same report last year.
This period
9.3M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+9.4
Same report last year
3.3M
History used
1,264 days
the 15 Jun 2021 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Government contracts: Federal obligations jump became public on 6 Jul 2021
Quest Diagnostics booked $7.3M in federal contract and grant obligations in June 2021, 1.0× the same month last year.
This period
$7.3M (June 2021)
Normal month (median of 5 earlier)
$1.6M
Typical spread (median absolute deviation)
$135K
How far from its usual level
+5.7
Same month last year
$7.2M
History used
5,021 days
June 20215 earlier monthsnormal: $1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 13 Jul 2021
Quest Diagnostics had 8.7M shares sold short in the 30 Jun 2021 report, 2.6× the same report last year.
This period
8.7M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
499K
How far from its usual level
+7.9
Same report last year
3.4M
History used
1,279 days
the 30 Jun 2021 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 27 Jul 2021
Quest Diagnostics reported revenue of $2.5B for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.
This period
$2.5B (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$2.0B
Typical spread (median absolute deviation)
$130.0M
How far from its usual level
+3.0
Same quarter last year
$1.8B
History used
4,748 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $2.0B
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Lobbying: Lobbying spend jump became public on 22 Jul 2021
Quest Diagnostics reported $340K of lobbying spend for the quarter ended 30 Jun 2021, 1.5× the same quarter last year.
This period
$340K (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$220K
Typical spread (median absolute deviation)
$10K
How far from its usual level
+5.5
Same quarter last year
$230K
History used
4,018 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $220K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Short interest and volume: Short interest spike became public on 27 Jul 2021
Quest Diagnostics had 8.1M shares sold short in the 15 Jul 2021 report, 2.5× the same report last year.
This period
8.1M (the 15 Jul 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
499K
How far from its usual level
+7.1
Same report last year
3.2M
History used
1,294 days
the 15 Jul 2021 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Aug 2021
Quest Diagnostics had 7.2M shares sold short in the 30 Jul 2021 report, 2.6× the same report last year.
This period
7.2M (the 30 Jul 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
636K
How far from its usual level
+4.6
Same report last year
2.8M
History used
1,309 days
the 30 Jul 2021 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
4 Nov 2026Government contracts change
booked $57.0M in federal contract and grant obligations in October 2026, 1.3× the same month last year.
Same month last year: $42.6M; its normal month is $35.6M.
See the evidence
This period
$57.0M (October 2026)
Normal month (median of 5 earlier)
$35.6M
Typical spread (median absolute deviation)
$929K
How far from its usual level
+6.0
Same month last year
$42.6M
History used
6,970 days
October 20265 earlier monthsnormal: $35.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Showing the newest 40 of 178 entries; narrow the window or the kind of data to see older ones.
Not listed: 313 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
100% American Medical Laboratories, Incorporated (DE), 100% AmeriPath Cincinnati, Inc. (OH), 100% AmeriPath Cleveland, Inc. (OH), 100% AmeriPath Consolidated Labs, Inc. (FL) and 82 more
Uei
CCYYREJXLFE3, GLPMEN5F8LZ1, NBHKGGN6DL95, R4SRLXUNDJK8 and 3 more
Wikidata
Q7271456
Wikipedia
Quest Diagnostics
DOL H-1B labor condition applications and PERM certifications1033 data points1 Oct 2019 to 28 Sep 2026
Federal lobbying disclosures (LDA)18 records, 240 data points30 Jun 1999 to 30 Sep 2026
SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)157 records28 Jan 2016 to 23 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1141 data points31 Dec 2006 to 15 Oct 2026
SEC Form 4 insider transactions178 records, 524 data points3 Mar 2016 to 16 Nov 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards311 records, 14400 data points1 Oct 2007 to 19 Nov 2026
WARN layoff notices (state labor agencies)2 records, 6 data points16 Apr 2007 to 1 Jun 2025
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026